What is he best known for?
The fields of study he is best known for:
His primary areas of study are Herpes simplex virus, Virology, Oncolytic virus, Molecular biology and Immune system.
His research in Herpes simplex virus intersects with topics in Oncolytic Virus Therapy, Vector and Pathology.
His Virology research includes themes of MHC class I and Mutant.
His Oncolytic virus research integrates issues from Brain tumor, Cancer stem cell and Glioma.
His Molecular biology study incorporates themes from Processivity, DNA clamp, DNA polymerase II, Gene and Klenow fragment.
He combines subjects such as Melanoma and Chemotherapy with his study of Virus.
His most cited work include:
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. (820 citations)
- Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas (674 citations)
- Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells (513 citations)
What are the main themes of his work throughout his whole career to date?
Samuel D. Rabkin spends much of his time researching Oncolytic virus, Herpes simplex virus, Virology, Cancer research and Virus.
His studies in Oncolytic virus integrate themes in fields like Cancer cell and Glioma.
The various areas that Samuel D. Rabkin examines in his Herpes simplex virus study include Cell culture, Viral replication, Vector, Molecular biology and Genetic enhancement.
Samuel D. Rabkin studied Virology and Gene that intersect with Cell.
His Cancer research study combines topics from a wide range of disciplines, such as Interleukin 12, Stem cell and In vivo.
His work carried out in the field of Cancer brings together such families of science as Chemotherapy, Combination therapy and Pathology.
He most often published in these fields:
- Oncolytic virus (52.31%)
- Herpes simplex virus (46.30%)
- Virology (40.28%)
What were the highlights of his more recent work (between 2011-2021)?
- Oncolytic virus (52.31%)
- Cancer research (39.81%)
- Herpes simplex virus (46.30%)
In recent papers he was focusing on the following fields of study:
Samuel D. Rabkin mainly investigates Oncolytic virus, Cancer research, Herpes simplex virus, Cancer cell and Virology.
His Oncolytic virus research is multidisciplinary, relying on both Cancer stem cell and Immunotherapy.
His study in Cancer research is interdisciplinary in nature, drawing from both Cytotoxic T cell, Interleukin 12 and In vivo.
His work deals with themes such as Cell culture, Viral replication, Chemotherapy, Malignant meningioma and Kinase, which intersect with Herpes simplex virus.
His work in the fields of Virology, such as Virus, overlaps with other areas such as Titration.
His biological study spans a wide range of topics, including Molecular biology and Cell.
Between 2011 and 2021, his most popular works were:
- Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells (513 citations)
- Oncolytic Viruses and Their Application to Cancer Immunotherapy (202 citations)
- Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade (191 citations)
In his most recent research, the most cited papers focused on:
Samuel D. Rabkin focuses on Oncolytic virus, Cancer research, Cancer cell, Immunology and Herpes simplex virus.
His Oncolytic virus research integrates issues from Tumor microenvironment, Cancer stem cell and Glioma.
His Cancer research study incorporates themes from DNA damage, Gene knockdown, Poly ADP ribose polymerase, Talimogene laherparepvec and Interleukin 12.
The concepts of his Cancer cell study are interwoven with issues in Immune checkpoint and Cancer immunotherapy.
His Herpes simplex virus study is concerned with Virus in general.
His research in Virology intersects with topics in Cytotoxic T cell and Apoptosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
